RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites

Small GTPases

Volumn 3, Issue 3, 2012, Pages 154-158

  Hollenhorst, Peter C ^a  

^a Indiana University School of Medicine   (United States)

Author keywords

AP 1; Cell migration; ERK; ETS; Prostate cancer; RAS signaling; Transcription

Indexed keywords

MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ELK 3; TRANSCRIPTION FACTOR ELK 4; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS1; TRANSCRIPTION FACTOR ETS2; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR RUNX; UNCLASSIFIED DRUG; WNT PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME REARRANGEMENT; ENZYME SPECIFICITY; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; MMP1 GENE; MMP9 GENE; NONHUMAN; PLAU GENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; NEOPLASM; TRANSCRIPTION INITIATION;

ANIMALS; BINDING SITES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 84863806062     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.19630     Document Type: Article

References (51)

1. Yang SH, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene 2003; 320:3-21; PMID:14597384; http://dx.doi.org/10.1016/S0378-1119(03)00816-3.
2. Imler JL, Schatz C, Wasylyk C, Chatton B, Wasylyk B. A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum. Nature 1988; 332:275-8; PMID:2831462; http:// dx.doi.org/10.1038/332275a0.
3. Satake M, Ibaraki T, Yamaguchi Y, Ito Y. Loss of responsiveness of an AP1-related factor, PEBP1, to 12-O-tetradecanoylphorbol-13-acetate after transformation of NIH 3T3 cells by the Ha-ras oncogene. J Virol 1989; 63:3669-77; PMID:2547991.
4. Yamaguchi Y, Satake M, Ito Y. Two overlapping sequence motifs within the polyomavirus enhancer are independently the targets of stimulation by both the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and the Ha-ras oncogene. J Virol 1989; 63:1040-8; PMID:2536818.
5. Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 1990; 346:191-3; PMID:2114554; http://dx.doi. org/10.1038/346191a0.
6. Nerlov C, Rørth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6:1583-92; PMID:1923525.
7. Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990; 9:2241-6; PMID:2162765.
8. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271:10672-80; PMID:8631874; http://dx.doi. org/10.1074/jbc.271.18.10672.
9. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011; 80:437-71; PMID:21548782; http://dx.doi. org/10.1146/annurev.biochem.79.081507.103945.
10. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117:5965-73; PMID:15564374; http://dx.doi. org/10.1242/jcs.01589.
11. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 2011; 25:2147-57; PMID:22012618; http:// dx.doi.org/10.1101/gad.17546311.
12. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETSfamily DNA-binding in vitro and in vivo. EMBO J 2010; 29:2147-60; PMID:20517297; http://dx.doi. org/10.1038/emboj.2010.106.
13. Hollenhorst PC, Jones DA, Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 2004; 32:5693-702; PMID:15498926; http:// dx.doi.org/10.1093/nar/gkh906.
14. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007; 21:1882-94; PMID:17652178; http://dx.doi.org/10.1101/ gad.1561707.
15. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 2009; 5:1000778; PMID:20019798; http://dx.doi.org/10.1371/journal. pgen.1000778.
16. Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, Lupien M, et al. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res 2009; 19:1963-73; PMID:19687146; http://dx.doi.org/10.1101/ gr.093047.109.
17. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8; PMID:16254181; http://dx.doi.org/10.1126/science. 1117679.
18. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007; 21:1835-46; PMID:17505060; http://dx.doi.org/10.1210/ me.2006-0480.
19. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448:595-9; PMID:17671502; http://dx.doi. org/10.1038/nature06024.
20. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10:177-88; PMID:18283340; http://dx.doi.org/10.1593/ neo.07822.
21. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68:73-80; PMID:18172298; http://dx.doi.org/10.1158/0008-5472.CAN-07-5352.
22. Hollenhorst PC, Paul L, Ferris MW, Graves BJ. The ETS gene ETV4 is required for anchorageindependent growth and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer 2011; 1:1044-52; PMID:21373373; http:// dx.doi.org/10.1177/1947601910395578.
23. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5; PMID:1522903; http://dx.doi. org/10.1038/359162a0.
24. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995; 11:1049-54; PMID:7566963.
25. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/ FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13:7393-8; PMID:8246959.
26. Mackintosh C, Madoz-Gúrpide J, Ordóñez JL, Osuna D, Herrero-Martín D. The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther 2010; 9:655-67; PMID:20215864; http://dx.doi. org/10.4161/cbt.9.9.11511.
27. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8:497-511; PMID:18563191; http:// dx.doi.org/10.1038/nrc2402.
28. Bassuk AG, Leiden JM. A direct physical association between ETS and AP-1 transcription factors in normal human T cells. Immunity 1995; 3:223-37; PMID:7648395; http://dx.doi.org/10.1016/1074-7613(95)90092-6.
29. Verger A, Buisine E, Carrère S, Wintjens R, Flourens A, Coll J, et al. Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation. J Biol Chem 2001; 276:17181-9; PMID:11278640; http:// dx.doi.org/10.1074/jbc.M010208200.
30. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res 1998; 75:1-55; PMID:9709806; http://dx.doi. org/10.1016/S0065-230X(08)60738-1.
31. Kim S, Denny CT, Wisdom R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 2006; 26:2467-78; PMID:16537893; http://dx.doi. org/10.1128/MCB.26.7.2467-78.2006.
32. Charlot C, Dubois-Pot H, Serchov T, Tourrette Y, Wasylyk B. A review of post-translational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response. Methods Mol Biol 2010; 647:3-30; PMID:20694658; http://dx.doi. org/10.1007/978-1-60761-738-9_1.
33. Valouev A, Johnson DS, Sundquist A, Medina C, Anton E, Batzoglou S, et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 2008; 5:829-34; PMID:19160518; http://dx.doi.org/10.1038/ nmeth.1246.
34. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000; 275:1216-25; PMID:10625666; http:// dx.doi.org/10.1074/jbc.275.2.1216.
35. Gu X, Zerbini LF, Out HH, Bhasin M, Yang Q, Joseph MG, et al. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67:4219-26; PMID:17483333; http://dx.doi.org/10.1158/0008-5472.CAN-06-3689.
36. Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, et al. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 2011; 71:1723-35; PMID:21446014; http://dx.doi. org/10.1002/pros.21389.
37. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003; 63:4626-31; PMID:12907642.
38. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007; 67:1618-25; PMID:17308102; http://dx.doi. org/10.1158/0008-5472.CAN-06-2913.
39. Moussa O, Turner DP, Feldman RJ, Sementchenko VI, McCarragher BD, Desouki MM, et al. PDEF is a negative regulator of colon cancer cell growth and migration. J Cell Biochem 2009; 108:1389-98; PMID:19830706; http://dx.doi.org/10.1002/ jcb.22371.
40. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 2008; 19:3745-57; PMID:18579687; http://dx.doi. org/10.1091/mbc.E08-02-0154.
41. Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, et al. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene 2008; 27:2877-85; PMID:18037958; http://dx.doi. org/10.1038/sj.onc.1210953.
42. O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 1996; 13:1323-33; PMID:8808707
43. Janknecht R. Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol 1996; 16:1550-6; PMID:8657129.
44. Janknecht R, Monté D, Baert JL, de Launoit Y. The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene 1996; 13:1745-54; PMID:8895521.
45. Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, et al. An oncogenic role for ETV1 in melanoma. Cancer Res 2010; 70:2075-84; PMID:20160028; http://dx.doi.org/10.1158/0008-5472.CAN-09-3092.
46. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76:1025-37; PMID:8137421; http://dx.doi.org/10.1016/0092-8674(94)90380-8.
47. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA, et al. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21:1370-83; PMID:11158322; http://dx.doi. org/10.1128/MCB.21.4.1370-83.2001.
48. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with betacatenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 2004; 279:20794-806; PMID:14990565; http://dx.doi.org/10.1074/jbc. M311131200.
49. Giese K, Kingsley C, Kirshner JR, Grosschedl R. Assembly and function of a TCRalpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev 1995; 9:995-1008; PMID:7774816; http:// dx.doi.org/10.1101/gad.9.8.995.
50. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, et al. FZD4 as a mediator of ERG oncogeneinduced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70:6735-45; PMID:20713528; http:// dx.doi.org/10.1158/0008-5472.CAN-10-0244.
51. Xin JH, Cowie A, Lachance P, Hassell JA. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Genes Dev 1992; 6:481-96; PMID:1547944; http://dx.doi. org/10.1101/gad.6.3.481.